Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement

Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services
Agreement

Agreement Underscores Morphotek's Commitment to the Development of
Farletuzumab for Ovarian Cancer

Agreement Highlights Lonza's Ability to Offer Specialty Development and
Manufacturing Solutions

EXTON, Pa. and BASEL, Switzerland, May 19 /PRNewswire/ -- Morphotek(R), Inc.,
a subsidiary of Eisai Corporation of North America, and Lonza Group Ltd
jointly announced today that they have executed a manufacturing services
agreement to support the development and manufacturing of a subset of
antibodies in Morphotek's therapeutic antibody pipeline. The agreement will
reserve capacity for commercial manufacturing of Morphotek's lead compound
farletuzumab (also known as MORAb-003), which recently entered Phase III
clinical trials for ovarian cancer under a Special Protocol Assessment (SPA)
agreement with the U.S. Food and Drug Administration (FDA). The collaboration
between both parties already encompasses several other monoclonal antibodies
currently in clinical or preclinical development.

"Lonza is an ideal partner and collaborator on this project," said Philip
Sass, PhD, Executive Vice President and Chief Operating Officer of Morphotek.
"They have a great deal of experience and expertise with large scale
expression and purification of commercial antibody products. They have
demonstrated their ability to develop high-quality material and documentation
with several of our programs and serve as an extension of our development team
at Morphotek. Based on our working experience, we are confident that Lonza
will meet our production, quality goals and timelines for our antibody
programs."

"Lonza is excited to participate in supporting the commercial manufacturing of
Morphotek's lead compound, farletuzumab," said Stephan Kutzer, Head of Lonza
Biopharmaceuticals. "Lonza looks forward to continuing and expanding the
Morphotek relationship for both development and manufacturing services using
Lonza's proprietary GS Gene Expression System(TM) toward their pipeline of
promising compounds."

Through the use of its proprietary MORPHODOMA(R) technology, Morphotek
develops optimized antibodies, including antibodies optimized for affinity
and/or titer, for therapeutic applications and high-titer manufacturing cell
lines. The antibodies within the company's pipeline are targeted against
antigens licensed from its collaborative partners. Through its technology and
collaborations, the company remains committed to bringing a new treatment
option for patients with ovarian cancer.

About Lonza
Lonza is one of the world's leading suppliers to the pharmaceutical,
healthcare and life science industries. Its products and services span its
customers' needs from research to final product manufacture. Lonza is the
global leader in the production and support of active pharmaceutical
ingredients, both chemically and biologically. Biopharmaceuticals are one of
the key growth drivers of the pharmaceutical and biotechnology industries.
Lonza has strong capabilities in large and small molecules, peptides, amino
acids and niche bioproducts which play an important role in the development of
novel medicines and healthcare products. Lonza is a leader in cell-based
research, endotoxin detection and cell therapy manufacturing. Lonza is also a
leading provider of value chemical and biotech ingredients to the nutrition,
hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss
Exchange. In 2008, Lonza had sales of CHF 2.937 billion. Further information
can be found at www.lonza.com.

About Morphotek
Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, is a
biopharmaceutical company specializing in the development of protein and
antibody products through the use of novel and proprietary technologies. These
technologies have been successfully applied to a variety of molecules that are
suitable for pharmaceutical product development in the areas of antibody
therapeutics, protein therapeutics, product manufacturing, drug target
discovery, and improved output traits for commercial applications. The company
is currently focusing its platform on the development and manufacturing of
therapeutic antibodies for the treatment of cancer, inflammation and
infectious disease. For more information, please visit www.morphotek.com.

About Eisai Corporation of North America
Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co.,
Ltd., a research-based human health care (hhc) company that discovers,
develops and markets products throughout the world. Eisai focuses its efforts
in three therapeutic areas: neurology, gastrointestinal disorders and
oncology/critical care. Eisai Corporation of North America supports the
activities of its operating companies in North America, which include: Eisai
Research Institute of Boston, Inc., a discovery operation with strong organic
chemistry capabilities; Morphotek, Inc., a biopharmaceutical company
specializing in the development of therapeutic monoclonal antibodies; Eisai
Medical Research Inc., a clinical development group; Eisai Inc., a commercial
operation with manufacturing and marketing/sales functions; and Eisai
Machinery U.S.A., which markets and maintains pharmaceutical manufacturing
machinery. For more information about Eisai, please visit www.eisai.com.

For further Information:
------------------------
Lonza Lonza
Head Corporate Communications Media Relations
Janet White Dominik Werner
Tel +41 61 316 8566 Tel +41 61 316 8798
Fax +41 61 316 9566 Fax +41 61 316 9798
janet.white@lonza.com dominik.werner@lonza.com

Lonza
Investor Relations
Alexandre Pasini
Tel +41 61 316 8835
Fax +41 61 316 9835
alexandre.pasini@lonza.com

Morphotek(R), Inc.
Executive Vice President and Chief Operating Officer
Philip M. Sass
Tel +1-610-423-6106
info@morphotek.com

Eisai Corporation of
North America
Senior Director, Corporate
Communications
Judee Shuler
+1-201-746-2241
Judee_Shuler@eisai.com

SOURCE Morphotek, Inc.

Head Corporate Communications, Janet White, +41 61 316 8566, fax, +41 61 316
9566, janet.white@lonza.com, or Media Relations, Dominik Werner, +41 61 316
8798, fax, +41 61 316 9798, dominik.werner@lonza.com, or Investor Relations,
Alexandre Pasini, +41 61 316 8835, fax, +41 61 316 9835,
alexandre.pasini@lonza.com, all of Lonza; or Philip M. Sass, Executive Vice
President and Chief Operating Officer of Morphotek(R), Inc., +1-610-423-6106,
info@morphotek.com; or Judee Shuler, Senior Director, Corporate Communications
of Eisai Corporation of North America, +1-201-746-2241,
Judee_Shuler@eisai.com